Add BrightSurf on Google Email

Similar timing and pattern: Seven European countries observe drop in chlamydia notifications especially among young people in 2024

Chlamydia notifications decreased in seven European countries, with significant declines among young people. The decline was mainly seen in Sweden, Denmark, England, Finland, Ireland, Norway and the Netherlands, with case numbers dropping by up to 32% in some countries.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateMay 28, 2026

Scientists from the University of Maryland School of Medicine and colleagues create the first-ever immune-capable “cervix-on-a-Chip” to study sexually transmitted infections (STIs)

Researchers developed an immune-capable 'cervix-on-a-Chip' model to study sexually transmitted infections (STIs), enabling a more accurate understanding of these conditions and the potential for better treatments. The model replicated key aspects of human biology, including the cervical microenvironment, microbiomes, and immune system.

SourceUniversity of Maryland School of Medicine·JournalScience Advances·TypeExperimental study·DateApr 3, 2026

Mini-organs reveal how the cervix defends itself

Researchers at Aarhus University used mini-organs to show that cervical epithelial cells actively detect and combat infections, with uninfected cells becoming immune-active. This discovery opens opportunities for mucosal vaccines and targeted treatments against STIs and infertility.

SourceAarhus University·JournalScience Advances·DateOct 3, 2025

Research reveals STIs during pregnancy linked to adverse birth complications

A large-scale study found strong links between maternal infections and adverse outcomes in babies born in Australia's Northern Territory. Congenital syphilis tripled the risk of preterm birth, while gonorrhoea increased the risk of stillbirth. The study highlights the need for more changes in STI testing during pregnancy.

SourceCurtin University·JournalThe Lancet Regional Health - Western Pacific·TypeData/statistical analysis·DateJul 21, 2025

Benefits and risks: informal use of antibiotics to prevent sexually transmitted infections on the rise in key populations in the Netherlands

A recent study in the Netherlands found 15% of men who have sex with men and transgender individuals recently used doxycycline as post- or pre-exposure prophylaxis (PrEP), highlighting an increase in informal use. The high intention to use PrEP among the population raises concerns about potential antimicrobial resistance (AMR) and chan...

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeSurvey·DateJul 3, 2025

Sydney koalas’ Catch-22

A recent study highlights the unique challenges facing Sydney's koala population, which is one of the last strongholds for New South Wales' koalas in NSW. The populations have low genetic diversity, making them highly susceptible to environmental threats and disease outbreaks.

SourceUniversity of Sydney·JournalConservation Genetics·TypeCase study·DateFeb 27, 2025

Curbing the global spread of sexually transmitted diseases

A team of scientists has developed a cutting-edge technology to analyze bacterial sexually transmitted infections (STIs) using genome sequencing. The 'target enrichment' method enables high-resolution analysis of Chlamydia trachomatis and other pathogens, revealing new insights into their transmission and development pathways.

SourceUniversity of Zurich·JournalMicrobial Genomics·TypeRandomized controlled/clinical trial·DateFeb 13, 2025

As prevention strategy for sexually transmitted infections rolls out, experts highlight both promise and knowledge gaps

The rollout of doxycycline as a prevention strategy for sexually transmitted infections (STIs) has shown promise in reducing syphilis and chlamydia rates, but its effectiveness on gonorrhea is limited. Close monitoring for antimicrobial resistance is necessary to ensure the long-term efficacy of doxy PEP.

Chlamydia can settle in the intestine

Researchers found that Chlamydia bacteria can persist in the intestines of humans, where they form a permanent reservoir and evade antibiotic treatment. The bacteria preferentially infect the inner cell layer of intestinal organoids, but not the outer epithelial layer.

SourceUniversity of Würzburg·JournalPLOS Pathogens·TypeExperimental study·DateAug 23, 2024

Chlamydia can infect gastrointestinal epithelial cells in the lab

Researchers have successfully infected gastrointestinal epithelial cells with Chlamydia trachomatis using lab-grown human organoids. This finding supports the theory that Chlamydia can form a reservoir in the human gut, highlighting the importance of further investigation into this potential reservoir.

SourcePLOS·JournalPLOS Pathogens·DateAug 22, 2024

Study highlights sex differences in notified infectious disease cases across Europe

A study analyzing 5.5 million EU/EEA infectious disease cases over 10 years found significant sex differences in notified male versus female cases for several diseases. The proportion of males ranged from 40-45% for pertussis and Shiga toxin-producing Escherichia coli infections to 75-80% for HIV/AIDS.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateAug 15, 2024

Only around half of individuals disclose or believe they should reveal having an STI prior to sexual intercourse, research to-date suggests

A review of research suggests that only around half of individuals feel comfortable disclosing their STI diagnosis to a partner before engaging in sexual activity. Comprehensive sex education is needed to prevent the spread of infections and support individuals with diagnosed STIs.

SourceTaylor & Francis Group·JournalThe Journal of Sex Research·TypeLiterature review·DateJun 6, 2024

Study reports chlamydia and gonorrhea more likely to be treated per CDC guidelines in males, younger patients and individuals identifying as Black or multiracial

A recent study found that nearly one-in-five chlamydia patients and one-in-four gonorrhea patients did not receive CDC-recommended treatment. Treatment rates were higher for individuals seen in public health clinics, particularly males, younger patients, and those identifying as Black or multiracial.

SourceRegenstrief Institute·JournalSexually Transmitted Diseases·DateApr 25, 2024

Exploring the relationship between HIV pre-exposure prophylaxis and the incidence of chlamydia, gonorrhea and syphilis – findings from Denmark

A Danish study found that PrEP use was associated with a more than twofold increase in chlamydia, gonorrhea, and syphilis diagnoses. The researchers suggest that changes in sexual risk-taking may lead people to seek PrEP rather than increased risks.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateMar 28, 2024

STI cases on the rise across Europe

European Centre for Disease Prevention and Control reports significant increase in STI cases across Europe, with gonorrhoea cases rising by 48%, syphilis cases by 34%, and chlamydia cases by 16%. The surge highlights the need for enhanced prevention, access to testing, and effective treatment to address this public health challenge.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateMar 7, 2024

Doxycycline prophylaxis use low and did not prevent STIs among cisgender women

A recent study found that doxycycline prophylaxis did not prevent bacterial sexually transmitted infections (STIs) among cisgender women, despite being prescribed to 18% of participants. The study also revealed high rates of antibiotic-resistant gonorrhea, which may be due to low adherence and limited treatment options.

SourceHennepin Healthcare Research Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 21, 2023

NIH-funded study finds doxycycline reduces sexually transmitted infections by two-thirds

A new study published in the New England Journal of Medicine found that doxycycline can reduce the incidence of syphilis, gonorrhea, and chlamydia by two-thirds when taken within 72 hours after condomless sex. The research also highlighted a slight increase in antibacterial resistance, emphasizing the need for further exploration.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalNew England Journal of Medicine·DateApr 6, 2023

Review of studies finds disparity in presumptive chlamydia and gonorrhea treatment rates despite CDC guidelines

A review of studies found that rates of presumptive treatment for chlamydia and gonorrhea vary widely, with some areas treating up to 84% of patients while others treated less than 4%. The disparity highlights the need for standardized treatment guidelines and consideration of social determinants of health.

SourceRegenstrief Institute·JournalSexually Transmitted Diseases·DateMar 1, 2023

Chlamydia’s stealthy cloaking device identified

Researchers at Duke University have discovered a protein called GarD that cloaks Chlamydia bacteria from the host cell's immune system, allowing it to evade detection and elimination. Mutating this protein makes the bacteria vulnerable to destruction, offering new avenues for treatment.

SourceDuke University·JournalCell Host & Microbe·TypeExperimental study·DateSep 8, 2022

Better education needed about oral sex disease risk, poll of young people shows

A new poll shows that most teens and young adults know it's possible to catch or spread a sexually transmitted infection by having unprotected oral sex, but over half underestimate the level of that risk. Young people also call for more education about the risks of oral sex and normalization of protection through popular culture.

SourceMichigan Medicine - University of Michigan·JournalThe Annals of Family Medicine·TypeSurvey·DateJan 27, 2022

NIAID officials call for innovative research on sexually transmitted infections

Experts from NIAID urge biomedical research community to refocus on STI research, emphasizing the need for innovative diagnostics, therapeutics, and vaccines. The authors highlight the critical need to address antimicrobial resistance and cooperation among researchers, healthcare providers, and community clinics.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalThe Journal of Infectious Diseases·DateSep 9, 2019

The Lancet Infectious Diseases: First ever phase 1 trial of genital chlamydia vaccine finds it is safe and provokes immune response

A new chlamydia vaccine has shown promising early signs of effectiveness in a phase 1 clinical trial, provoking an immune response in all participants. The vaccine, CTH522, demonstrated improved performance with added liposomes, producing higher antibody levels and a more consistent cell-mediated immune response.

SourceThe Lancet·JournalThe Lancet Infectious Diseases·DateAug 12, 2019